Company Valuation: Northwest Biotherapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2024 2025 2026 2027
Market Cap 1 364 358.4 260.1 -
Change - -1.53% -27.42% -
Enterprise Value (EV) 1 364 358.4 356.2 385
Change - -1.53% -0.61% 8.1%
P/E -3.93x -5.72x - -
PBR - - - -
PEG - 0.1x - -
Capitalization / Revenue - - - 6.68x
EV / Revenue - - - 9.89x
EV / EBITDA - - - -
EV / EBIT - - -5.29x -8.12x
EV / FCF - - -6.98x -9.45x
FCF Yield - - -14.3% -10.6%
Dividend per Share 2 - - - -
Rate of return - - - -
EPS 2 -0.07 -0.04 - -
Distribution rate - - - -
Net sales 1 - - - 38.93
EBITDA - - - -
EBIT 1 - - -67.3 -47.4
Net income -85.19 -61.48 - -
Net Debt 1 - - 96.08 124.9
Reference price 2 0.2748 0.2288 0.1525 0.1525
Nbr of stocks (in thousands) 1,324,666 1,566,728 1,705,638 -
Announcement Date 31/03/25 15/04/26 - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
21.02x7.45x14.97x1.41% 71.81B
31.3x9.02x28.11x0.04% 60.06B
32.1x6.85x17.78x-.--% 27.93B
-72.02x13.86x-70.68x-.--% 25.7B
-15.29x5.82x-7.32x-.--% 24.89B
28.46x5.35x17.81x-.--% 20.92B
42.74x15.97x32.4x0.35% 15.04B
17.96x5.35x12.5x-.--% 14.46B
1015.79x35.53x613.78x-.--% 13.87B
Average 122.45x 11.69x 73.26x 0.2% 30.52B
Weighted average by Cap. 64.22x 9.80x 39.37x 0.4%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. NWBO Stock
  4. NBYB Stock
  5. Valuation Northwest Biotherapeutics, Inc.